Oral lenvatinib exhibited with five-fold improvement in progression-free treatment of thyroid cancer
A recent study shows that oral lenvatinib shows increased delay in the progression of advanced thyroid cancer as compared to placebo treatment. While the former exhibited results showing 18 months of delayed pr...